Contribute Try STAT+ Today

The California insurance commissioner is supporting an unusual gambit by a patent attorney who filed a whistleblower lawsuit alleging that Allergan fraudulently obtained patents in order to stifle generic rivals and maintain high prices for two of its medicines.

In a May 2018 lawsuit, Zachery Silbersher accused Allergan, which was recently bought by AbbVie (ABBV), of providing false information to the U.S. Patent & Trademark Office concerning a pair of drugs used to combat Alzheimer’s symptoms. By doing so, the company won patents that, for a time, delayed generic competition and, as a result, allowed it to charge government health care programs monopoly prices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.